Pilocarpine - Controlled Therapeutics

Drug Profile

Pilocarpine - Controlled Therapeutics

Alternative Names: Pilobuc; Pilocarpine controlled release insert - Controlled Therapeutics

Latest Information Update: 19 Jun 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Controlled Therapeutics (Scotland)
  • Developer Controlled Therapeutics (Scotland); Marillion Pharmaceuticals
  • Class Alkaloids; Antiglaucomas; Furans; Imidazoles; Miotics; Small molecules
  • Mechanism of Action Muscarinic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Xerostomia

Most Recent Events

  • 19 Jun 2015 Discontinued - Phase-II for Xerostomia in United Kingdom (Buccal)
  • 01 Jun 2010 Pilocarpine buccal insert is still in phase II development for Xerostomia
  • 27 Feb 2008 Controlled Therapeutics' pilocarpine buccal insert licensed to Marillion Pharmaceuticals worldwide for the treatment of xerostomia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top